Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically treated with chemotherapy and allogeneic stem cell transplantation, however not all patients are eligible or able to tolerate these regimens, and many patients will experience relapse. Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated promising results in the treatment of B-cell lymphomas and is now being explored in AML.
In this podcast, Saar Gill, MD, PhD, of the Perelman School of Medicines, PA, Richard Aplenc, MD, PhD, MSCE, of the Children’s Hospital of Philadelphia, PA, Marion Subklewe, MD, of the LMU Hospital Munich in Germany, and Rizwan Romee, MD, of the Dana-Farber Cancer Institute, MA, discuss the latest data from clinical trials, comparing CAR-T therapy to other immunotherapeutic approaches, and outlining the potential role of CAR-NK cells in AML treatment.
The post Key updates on CAR-T & cellular therapy for AML appeared first on VJHemOnc.
